Loading...
XNASPRQR
Market cap275mUSD
Dec 24, Last price  
2.71USD
1D
1.52%
1Q
58.93%
Jan 2017
-45.51%
IPO
-83.69%
Name

ProQR Therapeutics NV

Chart & Performance

D1W1MN
XNAS:PRQR chart
P/E
—
P/S
41.28
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.93%
Rev. gr., 5y
5.68%
Revenues
7m
+61.36%
0313,0009,407,0002,282,000-1,529,0004,941,0001,933,00001,354,0004,037,0006,514,000
Net income
-28m
L-56.67%
-3,253,000-12,127,000-20,832,000-39,103,000-43,637,000-36,894,000-56,746,000-46,614,000-61,680,000-64,891,000-28,119,000
CFO
22m
P
-2,332,000-14,457,000-24,232,000-34,221,000-34,951,000-30,682,000-43,970,000-47,060,000-26,012,000-68,508,00021,548,000
Earnings
May 22, 2025

Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
URL
https://www.proqr.com/
IPO date
Sep 18, 2014
Employees
130
Domiciled in
NL
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,514
61.36%
4,037
198.15%
1,354
 
Cost of revenue
41,518
71,994
59,588
Unusual Expense (Income)
NOPBT
(35,004)
(67,957)
(58,234)
NOPBT Margin
Operating Taxes
(78)
96
117
Tax Rate
NOPAT
(34,926)
(68,053)
(58,351)
Net income
(28,119)
-56.67%
(64,891)
5.21%
(61,680)
32.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
347
14,122
108,477
BB yield
-0.22%
-5.33%
-21.10%
Debt
Debt current
1,614
3,887
6,305
Long-term debt
33,562
33,284
70,349
Deferred revenue
44,170
67,012
14,687
Other long-term liabilities
65,381
Net debt
(83,749)
(58,225)
(111,499)
Cash flow
Cash from operating activities
21,548
(68,508)
(26,012)
CAPEX
(3,646)
(708)
(484)
Cash from investing activities
4,278
(702)
(425)
Cash from financing activities
(2,275)
(30,890)
136,832
FCF
6,877
(109,286)
(57,217)
Balance
Cash
118,925
94,775
187,524
Long term investments
621
629
Excess cash
118,599
95,194
188,085
Stockholders' equity
(371,504)
(347,427)
(285,080)
Invested Capital
476,798
500,405
537,519
ROIC
ROCE
EV
Common stock shares outstanding
81,011
71,641
64,182
Price
1.98
-46.49%
3.70
-53.81%
8.01
90.71%
Market cap
160,403
-39.49%
265,073
-48.44%
514,102
144.51%
EV
76,654
206,464
401,999
EBITDA
(32,542)
(65,436)
(55,905)
EV/EBITDA
Interest
1,203
5,127
3,405
Interest/NOPBT